[{"bbox": [91, 99, 367, 130], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [614, 170, 1035, 198], "category": "Section-header", "text": "CAPITALISATION STATEMENT"}, {"bbox": [1414, 234, 1556, 262], "category": "Text", "text": "(â‚¹ in Lakhs)"}, {"bbox": [91, 262, 1556, 731], "category": "Table", "text": "<table><thead><tr><th rowspan=\"2\">Particulars</th><th>Pre Issue</th><th rowspan=\"2\">Post Issue*</th></tr><tr><th>As on 31st March, 2025</th></tr></thead><tbody><tr><td><strong>Borrowings</strong></td><td></td><td></td></tr><tr><td>Short Term Debt</td><td>5,546.09</td><td>-</td></tr><tr><td>Long Term Debt</td><td>10,948.89</td><td>-</td></tr><tr><td><strong>Total Debts</strong></td><td><strong>16,494.98</strong></td><td><strong>-</strong></td></tr><tr><td><strong>Shareholders' funds</strong></td><td></td><td></td></tr><tr><td>Equity share capital</td><td>157.50</td><td>*</td></tr><tr><td>Reserve and surplus</td><td>18,837.03</td><td>*</td></tr><tr><td><strong>Total shareholders' funds</strong></td><td><strong>18,994.53</strong></td><td><strong>*</strong></td></tr><tr><td><strong>Long Term Debt / Shareholders' funds</strong></td><td>0.58</td><td>*</td></tr><tr><td><strong>Total Debt / Shareholders' funds</strong></td><td>0.87</td><td>*</td></tr></tbody></table>"}, {"bbox": [94, 734, 908, 765], "category": "Text", "text": "* The corresponding post issue figures are not determinable at this stage."}, {"bbox": [91, 798, 169, 825], "category": "Section-header", "text": "Notes:"}, {"bbox": [91, 830, 1556, 894], "category": "List-item", "text": "1. Short term Debts represent which are expected to be paid/payable within 12 months and excludes instalment of term loans repayable within 12 months."}, {"bbox": [91, 895, 1556, 957], "category": "List-item", "text": "2. Long term Debts represent debts other than Short Term Debts as defined above but includes instalment of term loans repayable within 12 months grouped under other current liabilities."}, {"bbox": [91, 958, 1511, 989], "category": "List-item", "text": "3. The figures disclosed above are based on restated statement of Assets and Liabilities of the Company as at March 31, 2025."}, {"bbox": [802, 2171, 848, 2199], "category": "Page-footer", "text": "256"}]